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Abstract
Background: The objective of this study was to compare the pharmacokinetic profile of a novel,
once-daily, controlled-release formulation of hydromorphone (OROS® hydromorphone) under
fasting conditions with that immediately after a high-fat breakfast in healthy volunteers. The effect
of the opioid antagonist naltrexone on fasting hydromorphone pharmacokinetics also was
evaluated.
Methods: In an open-label, three-way, crossover study, 30 healthy volunteers were randomized
to receive a single dose of 16 mg OROS® hydromorphone under fasting conditions, 16 mg OROS®
hydromorphone under fed conditions, or 16 mg OROS® hydromorphone under fasting conditions
with a naltrexone 50-mg block. Plasma samples taken pre-dose and at regular intervals up to 48
hours post-dose were assayed for hydromorphone concentrations. Analysis of variance was
performed on log-transformed data; for mean ratios of 0.8 to 1.2 (20%), differences were
considered minimal. Bioequivalence was reached if 90% confidence intervals (CI) of treatment
mean ratios were between 80% and 125%.
Results: The mean geometric ratios of the fed and fasting treatment groups for maximum plasma
concentration (Cmax) and area under the concentration-time curve (AUC0-t; AUC0-∞) were within
20%. Confidence intervals were within 80% to 125% for AUC0-t and AUC0-∞ but were slightly higher
for Cmax (105.9% and 133.3%, respectively). With naltrexone block, the hydromorphone Cmax
increased by 39% and the terminal half-life decreased by 4.5 hours. There was no significant change
in Tmax, AUC0-t or AUC0-∞.
Conclusion: Standard bioavailability measures show minimal effect of food on the bioavailability
of hydromorphone from OROS® hydromorphone. Naltrexone co-administration results in a slight
increase in the rate of absorption but not the extent of absorption.
Trial Registration: Clinical Trials.gov NCT00399295
Background
Hydromorphone hydrochloride (HCl) is a semi-synthetic
opioid agonist that is widely used for the treatment of
severe chronic pain. Studies have shown that it is a potent
analgesic with a tolerability profile similar to that of mor-
phine and other opioid analgesic agents [1]. Dosage forms
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available for administration of hydromorphone include
immediate-release and extended-release formulations.
Immediate-release hydromorphone has a half-life of
approximately 2 to 3 hours [2,3], and therefore must be
administered every 4 to 6 hours to provide continuous
pain control.
A novel, once-daily, controlled-release formulation of
hydromorphone (Jurnista™, Janssen Pharmaceutica, N.V.,
Beerse, Belgium) is being evaluated in an effort to provide
consistent pain relief with convenient 24-hour dosing in
patients with severe chronic pain. The monophasic release
of hydromorphone from the controlled-release formula-
tion is achieved by utilization of the OROS® Push-Pull™
osmotic pump delivery system (ALZA Corporation,
Mountain View, CA) [4]. In initial studies, the consistent
release of hydromorphone over a 24-hour period has
been demonstrated in healthy volunteers [5], with steady-
state plasma concentrations achieved by 48 hours (i.e.,
after two doses or by the third dose) and sustained
throughout the 24-hour dosing interval [6]. Further eval-
uation also has confirmed that the pharmacokinetics of
OROS® hydromorphone are linear and dose-proportional
for the 8, 16, 32, and 64 mg doses [7].
The objective of the present study was to characterize the
pharmacokinetic profile of OROS® hydromorphone fol-
lowing a single dose in the presence and absence of food.
Food has been known to affect the absorption and dispo-
sition of several drugs, for both immediate-release and
extended-release preparations. The effect of food on
extended-release formulations, which typically have
higher drug content compared with conventional formu-
lation, is more worrisome. Extended-release formulations
in general are designed to prolong the duration of efficacy
and/or reduce drug's side effects. These advantages may be
compromised in the presence of a significant food effect.
However, osmotically controlled formulations are nearly
insensitive to the gastrointestinal environment, including
food [8,9].
Further, the effect of pretreatment with an opioid antago-
nist (naltrexone) on the pharmacokinetics of OROS®
hydromorphone was evaluated. Naltrexone acts competi-
tively at mu, kappa, and delta receptors in the central
nervous system [10] and has been shown to have an effect
on the pharmacokinetics of controlled-release morphine
[11].
Methods
Subjects
Study volunteers were required to be healthy, non-smok-
ing adults (aged 19 to 50 years) with a body weight
between 61 and 100 kg and within 10% of their recom-
mended weight range for height and body frame, based
on the 1984 Metropolitan Height and Weight Tables. At
screening, subjects were required to have a negative urine
test result for drugs of abuse, including cannabinoids, opi-
ates, cocaine, ethanol, and barbiturates, and no clinically
significant deviations from normal in laboratory test val-
ues.
Subjects who were intolerant of, hypersensitive to, or
dependent on opioid agonists or antagonists were
excluded, as were individuals who had psychological or
physical dependence on opiates, developed tolerance to
opiates, were known drug abusers or addicts, or had
undergone drug or alcohol detoxification. Also excluded
were subjects with gastrointestinal disorders; compro-
mised cardiac, respiratory, renal or hepatic function; psy-
chiatric abnormalities; or significant hematologic,
metabolic or central nervous system disorders. Those tak-
ing any long-term medication, including prescription
medications, or who had received enzyme-altering agents,
recreational drugs, or an investigational agent within 30
days of beginning the study, also were excluded. Female
subjects of childbearing potential were required to be fol-
lowing a medically recognized contraceptive program
prior to and during the study. A negative pregnancy test
was required each week, before the administration of
study medication. All subjects were required to provide
written informed consent. The study was approved by the
Institutional Review Board and was carried out according
to the Declaration of Helsinki and subsequent revisions.
Study design
This was an open-label, randomized, three-way crossover
study designed to compare the relative pharmacokinetic
profile of OROS® hydromorphone 16 mg under fasting
conditions with the profile of OROS® hydromorphone
given immediately after a high-fat meal. The study also
examined the effect of the opioid receptor antagonist nal-
trexone on the pharmacokinetics of OROS® hydromor-
phone in the fasting state.
Based on the assumption that the within-subject variabil-
ity is less than 20% (value guided by variability in expo-
sure following immediate-release hydromorphone) and
that there is a 5% difference between treatments, a sample
size of 30 subjects was estimated to provide 80% power to
demonstrate equivalence at the 0.05 level of significance.
Interventions
Subjects were randomized to receive one of the following
orally administered treatments during each of three study
periods (i.e., a different treatment during each phase).
Each treatment period was separated by a 7-day washout.
Treatment A consisted of 16 mg OROS® hydromorphone
under fasting conditions, and Treatment B consisted of 16
mg OROS® hydromorphone under fed conditions. Treat-BMC Clinical Pharmacology 2007, 7:2 http://www.biomedcentral.com/1472-6904/7/2
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ment C was 16 mg OROS® hydromorphone under fasting
conditions with a naltrexone block; naltrexone HCl 50 mg
was given 12 hours before, with, and 12 hours after
OROS®  hydromorphone. All subjects received OROS®
hydromorphone, whereas only those receiving Treatment
C also received the naltrexone block.
The medication sequence received by each subject was
determined by simple random assignment by subject
number. Subjects reported to the study center each
evening before an administration day and received
OROS®  hydromorphone after an overnight fast (10
hours). All study medications were given with water (240
mL). Volunteers receiving Treatment B consumed a stand-
ardized high-fat breakfast (approximately 50% of total
caloric content of the meal and 800 to 1000 calories)
immediately before administration of the study medica-
tion, as recommended by FDA CDER Guidelines for
Industry on Food-Effect Bioavailability and Fed Bioequiv-
alence Studies [12].
Plasma sampling
Venous blood samples for pharmacokinetic analysis were
collected pre-dose (time 0) and at 2, 4, 6, 8, 10, 12, 16, 20,
24, 30, 36, 42, and 48 hours post-dose. Plasma hydromor-
phone concentrations were measured using a validated
LC/MS/MS method (CEDRA Corporation, Austin, TX),
covering a range of 0.05 to 10.0 ng/mL. Calibration stand-
ards prepared for each of the sample sets were used to
monitor the inter-day precision of the assay. The coeffi-
cients of variation for the standards ranged from 1.9% to
11.7%. The absolute deviations ranged from 0.06% to
3.2%. Peak plasma concentration (Cmax), time to peak
plasma concentration (Tmax), terminal half-life (t1/2), and
area under the concentration-time curve for zero to time t
(AUC0-t) and zero to infinity (AUC0-∞) were calculated.
Safety assessments
Clinical laboratory evaluations were obtained at the pre-
treatment evaluation and before each treatment phase.
Adverse events were recorded throughout the study.
Statistical analysis
Log-transformed (ln) Cmax, AUC0-t, and AUC0-∞ data were
analyzed using an appropriate analysis of variance
(ANOVA) regression model. Treatments B and C were
evaluated using ANOVA mean ratios and confidence
intervals from log-transformed parameters, with Treat-
ment A as the reference. The ANOVA model included the
factors sequence, subject within sequence, phase, and
treatment. For means within 20% (i.e., mean ratios of 0.8
to 1.2), differences were considered minimal. Bioequiva-
lence was concluded if 90% confidence intervals (CIs) of
treatment mean ratios were between 80% and 125%. Tmax
was analyzed non-parametrically, without dose normali-
zation, using the Wilcoxon signed rank sum test to com-
pare differences between Treatments A and B, and
between Treatments A and C. Data for t1/2 were summa-
rized using descriptive statistics.
Results
Subjects
Thirty healthy volunteers (21 males, 9 females) were ran-
domized. Baseline demographics are summarized in
Table 1. One subject discontinued prematurely, without
receiving any study medication, because of an adverse
event that occurred after pre-opioid naltrexone adminis-
tration (Treatment C). Another subject discontinued dur-
ing the third study period (Treatment C), also after
receiving pre-opioid naltrexone. The third subject with-
drew for personal reasons.
The pharmacokinetic and statistical analyses include all
available data from the 27 subjects who completed the
study. Three of the 27 subjects had evaluable data only in
two treatments. The exclusion of these subjects did not
effect the bioequivalence conclusions, hence all data were
kept in the final analysis.
Pharmacokinetics
Pharmacokinetic parameters for OROS® hydromorphone
in fasted (alone and with naltrexone) and fed volunteers
are shown in Table 2.
Food effect (Treatment Regimen A vs. Treatment Regimen 
B)
The mean plasma hydromorphone concentrations and
time profiles for OROS® hydromorphone after adminis-
tration to healthy volunteers under fasting (Treatment A)
and fed (Treatment B) conditions are shown in Figure 1.
The mean profiles following the two treatments overlap
for the first 6 hours post-dose suggesting that food has no
effect on the initial rate of rise. However, mean overall
Cmax increased slightly when OROS® hydromorphone was
administered after a high-fat meal (1.352 ng/mL vs. 1.107
ng/mL). The mean ratio of ln Cmax was 1.189, indicating
that the means were within 20%. The 90% CI for the
mean ratio of the product means using log-transformed
data ranged from 105.9% to 133.3%.
Exposure to hydromorphone (expressed as the mean
AUC0-t) was 31.12 ng·h/mL in the fasting state and 30.20
ng·h/mL in the fed state, whereas the mean AUC0-∞ was
38.84 ng·h/mL in the fasting state and 36.09 ng·h/mL in
the fed state. The 90% CIs for the ratios of the product
means were within 80% and 125% for both AUC0-t
(84.9%–103.7%) and AUC0-∞ (81.9%; 99.4%).BMC Clinical Pharmacology 2007, 7:2 http://www.biomedcentral.com/1472-6904/7/2
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Median Tmax was achieved 4 hours earlier when OROS®
hydromorphone was administered under fed conditions
compared with fasting conditions (12 vs. 16 hours; P =
0.0062). The 90% CI for the difference between product
medians was -6.0046 to -1.9981. Mean t1/2 was approxi-
mately similar under fed and fasting conditions (Table 2).
The between-subject variability in hydromorphone expo-
sure was similar for the two treatments.
Naltrexone effect (Treatment Regimen A vs. Treatment 
Regimen C)
The mean plasma hydromorphone concentrations and
time profiles for OROS® hydromorphone after adminis-
tration with (Treatment C) and without (Treatment A)
naltrexone in fasting healthy volunteers are shown in Fig-
ure 2.
Naltrexone increased the mean Cmax from 1.107 ng/mL to
1.635 ng/mL, an increase of 39%. Moreover, the 90% CI
for the ratio of the product means using log-transformed
data (123.5%; 156.1%) fell outside the limits of bioequiv-
alence (80%–125%).
Hydromorphone exposure, in terms both of AUC0-t and
AUC0-∞, was similar in both treatment groups. The 90%
CIs for the ratios of the product means using log-trans-
Table 2: Pharmacokinetic parameters for hydromorphone after administration of OROS® hydromorphone to fasted and fed 
volunteers
Parameter Treatment Regimen A 
(fasting; n = 25)
Treatment Regimen B 
(fed; n = 27)
Treatment Regimen C 
(fasting with naltrexone block; n = 26)
Cmax (ng/mL)
Mean 1.107 1.352 1.635
SD 0.2058 0.3633 0.5708
Tmax (h)
Median 16.0 12.0 12.0
Range 6.0–36.0 6.0–20.0 6.0–24.0
t1/2 (h)
Mean 14.7 12.5 10.1
SD 6.07 5.22 3.95
AUC0-t (ng· h/mL)
Mean 31.12 30.20 33.97
SD 7.063 8.738 9.007
AUC0-∞(ng·h/mL)
Mean 38.84 36.09 37.24
SD 9.566 10.04 9.921
Table 1: Baseline characteristics
Characteristic All Participants (n = 30)
Sex, n (%)
Male 21 (70)
Female 9 (30)
Race, n (%)
Caucasian 27 (90)
Black 2 (7)
Hispanic 1 (3)
Age (years)
Mean 33.1
Range 19–49
Height (cm)
Mean 176
Range 163–191
Weight (kg)
Mean 77.2
Range 64.5–94.5BMC Clinical Pharmacology 2007, 7:2 http://www.biomedcentral.com/1472-6904/7/2
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formed data (96.7%; 118.5% and 85.0%; 103.0%, respec-
tively) were contained entirely within the 80%–125%
equivalence limits.
Median Tmax occurred 4 hours earlier when OROS® hydro-
morphone was administered with naltrexone (12 hours)
vs. without naltrexone (16 hours; P = 0.3493). Mean t1/2
was approximately 4.5 hours shorter with than without
naltrexone (10.06 vs. 14.66 hours). The between-subject
variability in hydromorphone exposure was similar for
the two treatments.
Safety
At least one adverse event was experienced by 24 of the 30
participants (80%). Apart from one episode of severe diz-
ziness during Treatment C (OROS® hydromorphone with
naltrexone), all events were of mild or moderate intensity.
The most frequently occurring adverse events were nausea
and asthenia (Table 3). Abnormalities in laboratory
results were minor and were not considered as adverse
events by the investigator. No serious adverse events were
reported during the study. Two patients discontinued the
study because of adverse events after the initial naltrexone
dose of Treatment C.
Discussion
Food can interfere with the bioavailability of a drug via
several mechanisms, including physically binding the
drug, altering gastric pH, inhibiting or inducing presys-
temic metabolism, changing hepatic blood flow, altering
drug solubility, and promoting disintegration of the drug
formulation. The latter effect is particularly important for
extended-release formulations because they contain larger
amounts of drug than conventional formulations.
Mean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS® hydromorphone 16 mg; fasting  conditions) and treatment B (OROS® hydromorphone 16 mg; fed conditions) Figure 1
Mean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS® hydromorphone 16 mg; fasting 
conditions) and treatment B (OROS® hydromorphone 16 mg; fed conditions).BMC Clinical Pharmacology 2007, 7:2 http://www.biomedcentral.com/1472-6904/7/2
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With immediate-release hydromorphone, there is a 24%
increase in AUC and approximately 25% decrease in Cmax
when taken with food as compared to the fasted state [13].
The effect of a high-fat meal is generally expected to be
seen within the first few hours (4–6) of dosing as it inter-
acts with the formulation in the stomach, delays gastric
emptying, and may have other effects on drugs absorption
and metabolism [14] or cause dose dumping due to dis-
ruption of the controlled-release mechanism of the for-
mulation. The results of this study show that
consumption of a high-fat meal immediately before dos-
ing with OROS® hydromorphone does not affect overall
hydromorphone exposure, and the overall mean Cmax is
within 20%. The median Tmax was lower with food (12
hours) compared with the fasting condition (16 hours),
but the mean plasma concentration profiles are generally
super-imposable, especially up to 6 hours post-dose (Fig-
ure 1). These results indicate that the controlled-release
properties of the formulation were maintained when
taken with food and that the effect of food on hydromor-
phone rate and extent of exposure is minimal compared
with immediate-release hydromorphone. This is in con-
trast to another controlled-release formulation (palla-
done), whose concentration increases significantly (1.5-
fold) when the drug is taken with food, especially during
the first 6 hours after dosing [15]. The lower median Tmax
and 20% increase in Cmax with OROS® hydromorphone
could be attributed to delayed gastric emptying with food,
resulting in the drug release in the small intestines for
longer duration where the drug absorption is more effi-
cient. Since the controlled-release nature of the formula-
tion is not affected, the slightly lower Tmax and higher Cmax
are not expected to be safety concerns for OROS® hydro-
morphone. No differences between male and female
patients were observed (data not shown); however, the
small number of female participants does not allow for
any definitive conclusions to be drawn.
Co-administration of OROS® hydromorphone with nal-
trexone under fasting conditions appeared to increase the
rate (but not the extent) of absorption of hydromor-
phone, with a 39% increase in Cmax and a 4.5-hour reduc-
Mean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS® hydromorphone 16 mg; fasting  conditions) and Treatment C (OROS® hydromorphone 16 mg; fasting conditions and naltrexone block) Figure 2
Mean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS® hydromorphone 16 mg; fasting 
conditions) and Treatment C (OROS® hydromorphone 16 mg; fasting conditions and naltrexone block).BMC Clinical Pharmacology 2007, 7:2 http://www.biomedcentral.com/1472-6904/7/2
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tion in t1/2. There was no significant change in Tmax, AUC0-
t, or AUC0-∞. These results with no effect on overall drug
exposure indicate that blockade of opioid effects by nal-
trexone is useful in comparative bioavailability studies of
high-dose opioids in healthy volunteers, with the assump-
tion that all treatments are affected similarly. The results
of this study are also consistent with a previous study in
which the effect of naltrexone on the pharmacokinetics of
controlled-release oral morphine sulfate was assessed
[11]. Naltrexone did not affect the concentration-time
curve for controlled-release morphine, but the AUC0–24
and Cmax were increased significantly, accompanied by a
significant decrease in apparent absorption half-life of
morphine. The Tmax and apparent elimination half-life of
morphine were not significantly affected. The dose of nal-
trexone used in that study was 100 mg [11]. A 50-mg dose
was chosen for the present study in an attempt to mini-
mize naltrexone-related adverse events.
Adverse events occurred in a similar proportion of
patients in each treatment arm and were mild to moderate
in intensity, with no serious adverse events occurring dur-
ing the study. The types of adverse events reported were
consistent with those expected for an opioid agonist and
antagonist, primarily affecting the gastrointestinal and
central nervous systems. The two patients who discontin-
ued because of adverse events did so after receiving the
first naltrexone dose (Treatment C) and before receiving
OROS® hydromorphone.
Conclusion
The effect of food on the bioavailability (rate or extent of
absorption) of hydromorphone from OROS® hydromor-
phone in healthy volunteers is considered to be minimal,
therefore it can be taken without regards to food. Con-
comitant administration of naltrexone slightly increases
the rate, but not the extent, of hydromorphone absorp-
tion from OROS® hydromorphone in fasting healthy vol-
unteers.
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